A provider briefing on the Budesonide/Formoterol (Symbicort) shortage in 2026: supply timeline, prescribing implications, alternatives, and patient tools.
Budesonide/Formoterol (Symbicort, Breyna) has been one of the more supply-challenged ICS/LABA inhalers over the past several years. While the situation has materially improved heading into 2026, providers should be aware of remaining availability nuances, prescribing implications, and tools available to help patients navigate access and cost barriers.
This briefing covers the supply timeline, current availability picture, cost landscape, and actionable steps providers can take to minimize treatment disruptions for their asthma and COPD patients.
Inhaler supply chains, already strained by pandemic-era disruptions, faced additional challenges in 2023. Metered-dose inhaler (MDI) manufacturing is technically complex — involving pressurized canisters, propellant systems, and metering valves — making it slower to recover from disruptions than oral solid-dose medications. Reports of Symbicort being unavailable at pharmacy level increased throughout the year.
Shortages persisted in 2024, though Symbicort was not placed on the FDA's critical shortage list. Wholesaler allocation limits created uneven geographic distribution, with certain markets (particularly rural areas and smaller pharmacy networks) disproportionately affected. Patients in well-served urban markets may not have experienced the issue, while patients in underserved areas reported weeks-long gaps.
The availability of generic Budesonide/Formoterol — including Breyna (Viatris) and authorized generics — significantly expanded the supply base. Multiple manufacturers producing the same molecule reduced reliance on a single supply chain and improved overall market resilience.
As of early 2026, Budesonide/Formoterol is not on the FDA's drug shortage list. National supply is adequate. However, localized disruptions remain possible, particularly during Q4 respiratory season when demand for all inhaler classes spikes. Providers should be prepared for occasional patient reports of pharmacy-level stock-outs.
The supply landscape has several practical implications for prescribers:
Unless you have a specific clinical reason to mandate brand-name Symbicort, writing prescriptions that allow generic substitution (or explicitly prescribing "budesonide/formoterol") gives the dispensing pharmacy maximum flexibility. This is especially important during supply-constrained periods.
Insurance formularies have shifted significantly with generic availability. Many plans now list generic Budesonide/Formoterol on Tier 2 (preferred generic) while moving brand-name Symbicort to Tier 3 or non-preferred. Checking your patient's formulary — or prescribing the generic by default — can reduce prior authorization requirements and patient cost burden.
Some payers require step therapy before authorizing ICS/LABA combinations. Patients who have previously failed a standalone ICS or whose clinical presentation clearly warrants combination therapy can often get step therapy overrides with appropriate clinical documentation.
Budesonide/Formoterol is approved for asthma in patients aged 6 and older. For pediatric patients, ensure the prescribed strength (80/4.5 mcg is the typical starting dose for children 6–11) is appropriate and that the child can properly use an MDI with a spacer if needed.
In 2026, providers and their patients can generally expect:
When patients report difficulty finding stock, it is most commonly a pharmacy-level issue (allocation limits or inventory decisions) rather than a true national shortage. Redirecting patients to check additional pharmacies — or using availability tools — usually resolves the issue.
Understanding the cost picture helps providers anticipate adherence barriers and proactively connect patients with savings resources.
For detailed savings guidance to share with patients, see our provider's guide to helping patients save on Budesonide/Formoterol.
Medfinder offers real-time pharmacy availability data that providers and care teams can use to direct patients to pharmacies with current stock. This is particularly useful when a patient reports difficulty filling a prescription and you need to identify an alternative pharmacy quickly.
When switching is clinically appropriate, the following alternatives are available:
For a patient-facing comparison to share, see our alternatives guide for Budesonide/Formoterol.
The ICS/LABA market is becoming more competitive, which generally benefits both availability and pricing. Key trends to watch:
The Budesonide/Formoterol supply situation in 2026 is substantially improved from the challenging 2023–2024 period. Generic availability has been the primary driver of this improvement. Providers can support their patients by prescribing generics when appropriate, staying aware of formulary dynamics, and connecting patients with availability tools like Medfinder and savings programs.
For related clinical resources, see our guide on helping your patients find Budesonide/Formoterol in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
